Why Did MiNK Therapeutics Plunge 31.92% After William Blair Downgrade?

On July 14, 2025, MiNK Therapeutics experienced a significant drop of 31.92% in pre-market trading, marking a notable decline in its stock performance.

William Blair, a prominent investment firm, recently downgraded MiNK Therapeutics from "Outperform" to "Market Perform." This change in rating reflects a more cautious outlook on the company's future prospects, which has likely contributed to the recent decline in its stock price.

The downgrade by William Blair suggests that the firm may have concerns about MiNK Therapeutics' ability to meet market expectations or achieve its strategic goals. This shift in sentiment can influence investor confidence and lead to a sell-off in the stock, as seen in the pre-market trading on July 14, 2025.